Article
Biochemistry & Molecular Biology
Michal Mielnik, Aneta Szudy-Szczyrek, Iwona Homa-Mlak, Radoslaw Mlak, Martyna Podgajna-Mielnik, Aneta Goracy, Teresa Malecka-Massalska, Marek Hus
Summary: This study assessed the correlation between pretreatment serum concentrations of IL-6, IL-8, MCP-1, and VEGF and the clinical outcomes of MM patients. Results showed that IL-8 was significantly correlated with age, staging, performance status, anemia, kidney disease, and VEGF. Chemotherapy responders had lower IL-8, IL-6, and VEGF concentrations compared to non-responders. High levels of IL-6 were associated with a higher risk of disease progression and reduced overall survival.
Review
Oncology
Chuqi Wang, Ming Chu
Summary: Metastasis of cancer cells through lymphatic vessels is a major cause of death in patients with malignancies. Recent studies have shown that tumor-induced lymphangiogenesis is closely related to lymphatic metastasis and poor clinical outcomes, providing new potential therapeutic targets for cancer treatment. This review provides an updated summary of the current advances in therapies preventing lymphatic metastasis and discusses the validity of different applications.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Richard D. Baird, Constanza Linossi, Mark Middleton, Simon Lord, Adrian Harris, Jordi Rodon, Christof Zitt, Ulrike Fiedler, Keith M. Dawson, Nicolas Leupin, Michael T. Stumpp, Andreas Harstrick, Analia Azaro, Stefanie Fischer, Aurelius Omlin
Summary: MP0250 is a first-in-class DARPin drug candidate with suitable tolerability and appropriate pharmacokinetic properties for further development in combination with other anticancer therapies. Signs of single-agent antitumor activity were observed.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
Ying Chen, Lina Zhang, Xiaoyan Zang, Xuxing Shen, Jianyong Li, Lijuan Chen
Summary: This study reveals for the first time that Baohuoside I (BI) inhibits angiogenesis in multiple myeloma (MM) through the PPARγ-VEGF signaling axis.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Selvaraj Vimalraj
Summary: Angiogenesis is the formation of new blood vessels from existing ones. Abnormal angiogenesis, seen in tumor microenvironments, is characterized by distorted and leaky blood vessels with various shapes and high perfusion efficiency. Tumor angiogenesis plays a crucial role in cancer growth, invasion, and metastasis, and is tightly regulated by signaling networks. Targeting multiple signaling pathways involved in angiogenesis is important for effective antiangiogenic therapy. New therapeutic approaches, such as blocking specific proteins or genes, are being explored to dissect alternative angiogenesis mechanisms in tumor microenvironments.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2022)
Article
Pharmacology & Pharmacy
Weifeng Wan, Xin Zhang, Changren Huang, Ligang Chen, Xiaobo Yang, Kunyang Bao, Tangming Peng
Summary: BAY1143269 is a novel inhibitor that can suppress angiogenesis in glioblastoma and exhibits anti-cancer activity. It acts on glioblastoma cells by inhibiting eIF4E-mediated expression of oncogenic proteins, providing an effective approach for anti-glioblastoma therapy.
PHARMACOLOGY RESEARCH & PERSPECTIVES
(2022)
Article
Oncology
Anna Russignan, Giada Dal Collo, Anna Bagnato, Nicola Tamassia, Mattia Bugatti, Mirella Belleri, Luisa Lorenzi, Enrica Borsi, Riccardo Bazzoni, Michele Gottardi, Carolina Terragna, William Vermi, Arianna Giacomini, Marco Presta, Marco Antonio Cassatella, Mauro Krampera, Cristina Tecchio
Summary: Macitentan effectively targets ET-1 receptors to inhibit MM cell survival and reduce pro-angiogenic cytokine release by modulating MAPK/ERK and HIF-1 alpha pathways, suggesting its potential as an anti-proliferative and anti-angiogenic therapy in MM preclinical models.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Sivaraman Kuppuswamy, Brian H. Annex, Vijay C. Ganta
Summary: VEGF(165)b inhibition improves perfusion recovery in preclinical PAD models with impaired VEGFR2-NO signaling by increasing microvascular density and activating VEGFR1-STAT3 signaling.
Article
Pharmacology & Pharmacy
Huan-Yu Zhao, Yi-Pan Zhu, Ying Wen, Xin-Yu Ding, Jing Sun, Ren-Peng Ji, Qiu-Ju Han, Lu-Yuan Li
Summary: In this study, it was found that MCP-1 promotes VEGF production while miR-374b-5p inhibits it by targeting the 3'-untranslated region of VEGF mRNA. MCP-1 also enhances the acetylation of transcription factor stat3, resulting in decreased expression of miR-374b-5p and increased VEGF production. Inhibiting stat3 acetylation, DNMT1, or EZH2 can effectively inhibit MCP-1-induced neovascularization and tumor growth.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Oncology
Metis Hasipek, Dale Grabowski, Yihong Guan, Raghunandan Reddy Alugubelli, Anand D. Tiwari, Xiaorong Gu, Gabriel A. DeAvila, Ariosto S. Silva, Mark B. Meads, Yvonne Parker, Daniel J. Lindner, Yogen Saunthararajah, Kenneth H. Shain, Jaroslaw P. Maciejewski, Frederic J. Reu, James G. Phillips, Babal K. Jha
Summary: PDIA1 is essential for the folding and structural integrity of antibodies and cytokines in multiple myeloma cells, making it a potential target for therapy. The PDIA1 inhibitor CCF642-34 induces apoptosis in myeloma cells and may overcome treatment-refractory states, suggesting its potential as an effective treatment option.
Review
Biochemistry & Molecular Biology
Alexandru Florea, Felix M. Mottaghy, Matthias Bauwens
Summary: Angiogenesis plays a crucial role in tumor growth, with molecular imaging becoming an integral part of cancer therapy. Both direct and indirect targeting tracers show potential value in clinical settings. Combining multiple targeting tracers into one agent may be a promising approach for evaluating tumor vascularization and vitality in the future.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Multidisciplinary
Menghuan Zhao, Peixin Guan, Shuxin Xu, Haifeng Lu, Zhen Liu
Summary: This study reports the rational engineering of VEGF-targeted molecularly imprinted polymer nanoparticles for anti-angiogenic cancer therapy. These nanoparticles can effectively block the signaling of vascular endothelial growth factor and demonstrate anti-angiogenic effects in vivo.
Article
Engineering, Biomedical
Xiaojun Zhang, Mazharul Karim, Farzana Alam, Faleh Alqahtani, Sireesha Y. Reddy, In-San Kim, Taslim A. Al-Hilal, Youngro Byun, Jeong Uk Choi, Md Mahedi Hasan, Seung Woo Chung
Summary: Growth factors play a crucial role in regulating normal development to cancer progression. Biomaterials that modulate GF activity by mimicking interactions observed in the native ECM could be designed as an effective treatment strategy. GAG-based materials can be designed to imitate and leverage bio-inspired interactions to control the tumor microenvironment.
Article
Oncology
Samah Elsaadi, Ida Steiro, Pegah Abdollahi, Esten N. Vandsemb, Rui Yang, Tobias S. Slordahl, Torstein Baade Ro, Eline Menu, Anne-Marit Sponaas, Magne Borset
Summary: The study demonstrates the therapeutic potential of targeting PHGDH in multiple myeloma, suggesting it as a way to overcome resistance to proteasome inhibitors.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Jiliang Xia, Jingyu Zhang, Xuan Wu, Wanqing Du, Yinghong Zhu, Xing Liu, Zhenhao Liu, Bin Meng, Jiaojiao Guo, Qin Yang, Yihui Wang, Qinglin Wang, Xiangling Feng, Guoxiang Xie, Yi Shen, Yanjuan He, Juanjuan Xiang, Minghua Wu, Gang An, Lugui Qiu, Wei Jia, Wen Zhou
Summary: This study reveals that the elevated glycine level in the bone marrow microenvironment of multiple myeloma is associated with MM progression, and MM cells utilize the SLC6A9 protein to absorb glycine for the synthesis of glutathione and purines.
NATURE COMMUNICATIONS
(2022)